- Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease
- New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)
- Roche Annual General Meeting 2023
- Assemblée générale 2023 de Roche
- Roche Generalversammlung 2023
- FDA Advisory Committee votes in favour of the clinical benefit of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
- Roche launches two new antibodies to identify key clinical mutations in patients with brain cancer
- [Ad hoc announcement pursuant to Art. 53 LR] Transaction in Roche bearer shares
- [Ad hoc-Mitteilung gemäss Art. 53 KR] Transaktion in Roche Inhaberaktien
- New phase III data show Roche’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO)
More ▼
Key statistics
On Thursday, Roche Holding AG (ROGN:MEX) closed at 5,187.44, 0.00% above its 52-week low of 5,187.44, set on Mar 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 5,187.44 |
Average volume | 1.90k |
---|---|
Shares outstanding | 809.25m |
Free float | 721.97m |
P/E (TTM) | 16.83 |
Market cap | 211.10bn CHF |
EPS (TTM) | 15.36 CHF |
Annual div (ADY) | 203.76 MXN |
---|---|
Annual div yield (ADY) | 3.93% |
Div ex-date | Mar 17 2022 |
Div pay-date | Mar 21 2022 |
Data delayed at least 20 minutes, as of Mar 23 2023 11:30 BST.
More ▼